Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BsUFA III Expands Biosimilar Supplement Review Goals To Speed Approvals

Executive Summary

Six supplement categories based on submission content will be created with review goals between three and 10 months.

You may also be interested in...



US FDA Making BsUFA III Regulatory Science Grants Available Early

Up to $1m per year per award is available for projects that address significant issues with biosimilar or interchangeable product development.

US FDA Making BsUFA III Regulatory Science Grants Available Early

Up to $1m per year per award is available for projects that address significant issues with biosimilar or interchangeable product development.

Is CREATES Act Equipped To Handle Biosimilar Complaints?

Biosimilar sponsors need multiple reference product lots and expiration dates, and questions remain about whether they can obtain enough to fulfill all regulatory requirements under a CREATES Act mandate, Teva attorney says.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS144979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel